{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:03:06Z","timestamp":1780081386666,"version":"3.54.0"},"reference-count":25,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Aromatase inhibitors (AIs) are widely used in hormone receptor-positive breast cancer but may adversely affect bone health. Evidence on their independent association with fracture risk compared with tamoxifen (TAM) remains inconsistent. Methods: In this retrospective cohort study, women with an initial prescription of TAM or AIs between 2016 and 2024 were identified in the IQVIA Longitudinal Prescription (LRx) database. Their prescription histories were combined with records from the IQVIA Disease Analyzer (DA) database using a validated co-therapy-based approach. Patients were then followed for up to five years. Kaplan\u2013Meier analyses estimated cumulative fracture incidence, and Cox regression models assessed associations in unadjusted, age-adjusted, and fully adjusted analyses. Results: The study included 8938 TAM users and 14,594 AI users. Five-year cumulative incidence of all fractures was higher in the AI group than in the TAM group (14.8% vs. 9.2%). In fully adjusted primary analyses, AI therapy was not significantly associated with overall fracture risk (HR 1.10, 95% CI 0.99\u20131.23). A modest association persisted for major osteoporotic fractures (HR 1.24, 95% CI 1.05\u20131.46). Secondary exploratory analyses (age-stratified and fracture-type-specific models) showed patterns consistent with the primary results but were not powered or corrected for confirmatory inference. Conclusions: Aromatase inhibitor therapy was associated with a higher fracture incidence than tamoxifen, but much of this difference was explained by age and comorbidities. Both treatment-related effects and underlying patient characteristics contribute to fracture risk, underscoring the importance of individualized bone health assessment and targeted preventive strategies in women receiving endocrine therapy.<\/jats:p>","DOI":"10.3390\/curroncol33060322","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:36:18Z","timestamp":1780076178000},"page":"322","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Endocrine Therapy and Fracture Risk in Women with Breast Cancer in Germany\u2014A Retrospective Cohort Study"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7227","authenticated-orcid":false,"given":"Karel","family":"Kostev","sequence":"first","affiliation":[{"name":"University of Marburg, Department of Gynecology and Obstetrics, University Hospital Marburg, 35043 Marburg, Germany"},{"name":"Epidemiology, IQVIA, 60549 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Peters","sequence":"additional","affiliation":[{"name":"Real-World Data Analytics, IQVIA, 60549 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Sievert","sequence":"additional","affiliation":[{"name":"Real-World Solutions, IQVIA, 60549 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kalder","sequence":"additional","affiliation":[{"name":"University of Marburg, Department of Gynecology and Obstetrics, University Hospital Marburg, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"GBD 2023 Breast Cancer Collaborators (2026). Global, regional, and national burden of breast cancer among females, 1990\u20132023, with forecasts to 2050: A systematic analysis for the Global Burden of Disease Study 2023. Lancet Oncol., 27, 302\u2013326.","DOI":"10.2139\/ssrn.6468038"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Smolarz, B., Nowak, A.Z., and Romanowicz, H. (2022). Breast Cancer\u2014Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers, 14.","DOI":"10.3390\/cancers14102569"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tong, C.W.S., Wu, M., Cho, W.C.S., and To, K.K.W. (2018). Recent Advances in the Treatment of Breast Cancer. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00227"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1038\/s41598-022-12228-y","article-title":"Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred","volume":"12","author":"Font","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Burciu, O.M., Merce, A.G., Cerbu, S., Iancu, A., Popoiu, T.A., Cobec, I.M., Sas, I., and Dimofte, G.M. (2025). Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning. Medicina, 61.","DOI":"10.3390\/medicina61071280"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet, 386, 1341\u20131352.","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1759720X18759291","article-title":"Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: A systematic review and meta-analysis","volume":"10","author":"Tseng","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Qu, H., Wang, J., Wang, Z., Guan, B., and Zheng, Y. (2025). Impact of different endocrine therapies on bone mineral density and fracture risk in postmenopausal breast cancer patients: A meta-analysis. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1665389"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cho, H., Kim, B., Han, K., Kim, S., Cho, I.Y., and Shin, D.W. (2026). Increased risk of fracture among breast cancer patients: A nationwide retrospective cohort study. J. Cancer Surviv.","DOI":"10.1007\/s11764-026-01980-z"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13058-025-02050-5","article-title":"Aromatase inhibitors therapy and major osteoporotic fracture risk in postmenopausal breast cancer patients: A nationwide real-world cohort study","volume":"27","author":"Liu","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/jbmr.3726","article-title":"Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study","volume":"34","author":"Leslie","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s00198-025-07639-2","article-title":"Differential fracture risk in breast cancer patients based on endocrine therapy and age: A nationwide cohort study","volume":"36","author":"Kwak","year":"2025","journal-title":"Osteoporos. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.breast.2021.09.010","article-title":"The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada","volume":"60","author":"Blanchette","year":"2021","journal-title":"Breast"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5414\/CP204485","article-title":"German longitudinal prescription database (LRx): Description of characteristics, use in pharmacoepidemiological research, and limitations","volume":"62","author":"Kostev","year":"2024","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5414\/CP203320","article-title":"Basic characteristics and representativeness of the German Disease Analyzer database","volume":"56","author":"Rathmann","year":"2018","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s11764-017-0666-4","article-title":"Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy","volume":"12","author":"Neuner","year":"2018","journal-title":"J. Cancer Surviv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00198-018-4642-2","article-title":"The tamoxifen paradox\u2014Influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer","volume":"29","author":"Kyvernitakis","year":"2018","journal-title":"Osteoporos. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/gerona\/glt092","article-title":"Epidemiology of fracture risk with advancing age","volume":"68","author":"Ensrud","year":"2013","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eprac.2023.03.001","article-title":"Age-Related Factors Associated With The Risk of Hip Fracture","volume":"29","author":"Buzkova","year":"2023","journal-title":"Endocr. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial","volume":"21","author":"Eastell","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"dgaa463","DOI":"10.1210\/clinem\/dgaa463","article-title":"Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors","volume":"105","author":"Rachner","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J. Bone Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/322\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:06:54Z","timestamp":1780078014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060322"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060322","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}